Antibiotic Treatment Duration in Critical Care Infections

Determining the optimal length of antibiotic therapy in critically ill patients remains a cornerstone of intensive care practice. Treatment duration must strike a balance between ensuring eradication of invasive pathogens and minimising the emergence of antimicrobial resistance, adverse events and costs. In infections such as ventilator-associated pneumonia and bloodstream infections, prolonged courses have traditionally been prescribed on the assumption that critical illness or resistant organisms warrant extended exposure. However, mounting evidence supports individualised or shorter regimens guided by clinical response, microbiological data and, where available, biomarkers. Shorter courses can reduce drug-related toxicity, limit disturbance of the microbiome and curb the selection pressure for resistant bacteria—an especially urgent priority in both high- and low-resource settings. Conversely, excessively abbreviated therapy risks relapse, recrudescence and complications. Current research is refining parameters for fixed-duration versus response-driven strategies, exploring novel diagnostic tools and modelling the population-level impact of varying treatment lengths. Such work underpins evolving guidelines that emphasise precision, stewardship and global applicability, with the dual aims of safeguarding patient outcomes and preserving antibiotic effectiveness for future generations.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Antibiotic Treatment Duration in Critical Care Infections publication trend

The graph below shows the total number of articles in antibiotic treatment duration in critical care infections across all publications each year (not limited to Nature Index journals).

Technical terms

Ventilator-associated pneumonia (VAP): A lung infection occurring ≥48 hours after endotracheal intubation and mechanical ventilation, characterised by fever, purulent secretions and new radiographic infiltrates.

Antimicrobial stewardship: A coordinated programme of interventions designed to improve and measure the appropriate use of antibiotics by optimising treatment selection, dosing, duration and route of administration.

Multidrug-resistant (MDR) pathogen: A microorganism resistant to at least one agent in three or more antimicrobial categories, posing significant challenges in critical care settings.

Non-inferiority trial: A study design that aims to demonstrate that a new treatment is not unacceptably worse than an established therapy by a pre-specified margin.

Meta-analysis: A statistical method that combines data from multiple studies to produce a single estimate of treatment effect, increasing power and precision.

References

1. Individualised, short-course antibiotic treatment versus usual long-course treatment for ventilator-associated pneumonia (REGARD-VAP): a multicentre, individually randomised, open-label, non-inferiority trial. The Lancet Respiratory Medicine (2024).
2. Implications of reducing antibiotic treatment duration for antimicrobial resistance in hospital settings: A modelling study and meta-analysis. PLOS Medicine (2023).
3. Short versus long course of colistin treatment for carbapenem-resistant A. baumannii in critically ill patients: A propensity score matching study. Journal of Infection and Public Health (2023).